| Document |
Document Title |
|
JP5701832B2 |
The present invention provides a method represented by Scheme 1: wherein X represents I, Br, Cl, alkylsulfonate, or arylsulfonate; Z represents optionally substituted aryl, heteroaryl or alkenyl; L represents hydrogen or a negative charg...
|
|
JP5642995B2 |
New 1,2,3- or 1,2,3,4- or 1,2,3,4,5- substituted imidazolium salts and their uses as solvent in catalyzed organic reactions, as well as compositions containing them and a transition metal compound. They can be used in the following react...
|
|
JP5603733B2 |
Ionic compound with low melting point has cation of the onium type with at least one heteroatom such as N, O, S or P; and anion which includes, wholly or partially, at least one imide ion. Independent claims are also included for: (1) el...
|
|
JP5582604B2 |
There is provided a compound of Formula (I), wherein each T is independently selected from H, hydrocarbyl, -F-R, and a bond with one of D, E, P or Q, or together with one of P and Q forms a ring; Z is a suitable atom the valency of which...
|
|
JP2014040488A |
To provide a new compound appropriate for inhibiting the steroid sulfatase activity and the aromatase activity.A compound represented by formula (I) is provided, where each T represents a bond with one of H, hydrocarbyl, -F-R- and D, E, ...
|
|
JP5405326B2 |
Topical formulations and method of using the same are provided. The topical formulation comprises a pyrazolylbenzothiazole derivative of the following formula (1) wherein X, R1, R2, R3 and R4 are described herein.
|
|
JP5372867B2 |
Disclosed is a compound represented by formula 1: [formula 1] wherein each of A, X, Y, Y' and Y'' has the same meaning as described herein. When used in an organic light emitting device, the compound represented by formula 1 has at least...
|
|
JP2013213068A |
To provide new therapeutic agents to treat human diseases.There are provided compounds that are protein kinase inhibitors, compositions containing such compounds and methods of use. More particularly, there are also provided compounds th...
|
|
JP5307747B2 |
The present invention relates to a process for the preparation of bis(perfluoroalkyl)phosphinic acids comprising at least the reaction of at least one difluorotris(perfluoroalkyl)phosphorane or at least one trifluorobis(perfluoroalkyl)ph...
|
|
JP5291854B2 |
The present invention provides a method represented by Scheme 1: wherein X represents I, Br, Cl, alkylsulfonate, or arylsulfonate; Z represents optionally substituted aryl, heteroaryl or alkenyl; L represents hydrogen or a negative charg...
|
|
JP5279161B2 |
Substituted aryloxyalkylamines of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.
|
|
JP5266499B2 |
The present invention provides a method represented by Scheme 1: wherein X represents I, Br, Cl, alkylsulfonate, or arylsulfonate; Z represents optionally substituted aryl, heteroaryl or alkenyl; L represents hydrogen or a negative charg...
|
|
JP5260818B2 |
The invention includes low molecular weight, non-peptidic, non-peptidommetic, organic molecules that can act as modulators of mammalian complement C5a receptors, preferably ones that act as high affinity C5a receptor ligands and also suc...
|
|
JP5249842B2 |
This invention describes novel pyrazole compounds of formula (I), wherein R 1 is T-Ring D, wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R x ,...
|
|
JP5242612B2 |
Disclosed is a compound represented by formula 1: [formula 1] wherein each of A, X, Y, Y' and Y'' has the same meaning as described herein. When used in an organic light emitting device, the compound represented by formula 1 has at least...
|
|
JP5236135B2 |
An ionic liquid of the formula K+A- wherein K+ and A- are as defined herein, are suitable for use in electrochemical cells and capacitors. These ionic liquids can also be used in catalysis, as inert solvents, and as hydraulic liquids.
|
|
JP5218788B2 |
A retroviral protease inhibiting compound of formula (A) is disclosed for use in combination with other active pharmaceutical agents for treating a human infected by HIV. Intermediates and processes useful in the manufacture of compounds...
|
|
JP5209670B2 |
Novel heterocyclo compounds useful as inhibitor of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activating del...
|
|
JP5196660B2 |
The present invention relates to compounds of the formula I or a pharmaceutically acceptable derivative thereof. The compounds are useful as inhibitors of bacterial gyrase activity. The present invention also relates to methods for treat...
|
|
JP5148646B2 |
Novel cycloalkyl compounds useful as inhibitors of potassium channel function (especially inhibitors of the K v l subfamily of voltage gated K + channels, especially inhibitors K v 1.5 which has been linked to the ultra-rapidly activatin...
|
|
JP5132861B2 |
This invention relates to compounds having the Formula I: or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein Het and R5-R8 are set in the specification. The invention also is directed to the use of compounds of Fo...
|
|
JP5118502B2 |
Compounds I-III wherein U is CH, O, or S; Z is mono- or di-substituted carbon; R is (CH2)nCO2H, (CH2)nSO3H, (CH2)nPO3H2, (CH2)nNO2, CH(SCH3)3, esters; R1 is H, hydroxyalkyl, aminoalkyl, alkoxyalkyl; RR1 is O; n is 0-4; R2, R3 is H, hydro...
|
|
JP5113976B2 |
Novel sulphones of Formula I are disclosed: wherein A completes a 4-7 membered ring optionally comprising up to two heteroatoms. The compounds modulate the action of gamma-secretase and are therefore useful in the treatment or prevention...
|
|
JP5095070B2 |
The invention relates to R-(-)-1-[2-(7-Chloro-benzo[b]thiophen-3-yl-methoxy)-2-(2,4-d
ichloro-phenyl)-ethyl]-1H-imidazole and the salts thereof. The invention also relates to compositions thereof and their use either for treating fungal ...
|
|
JP5089004B2 |
The invention provides pharmaceutical formulation comprising voriconazole, or a pharmaceutically acceptable derivative thereof, and a sulfobutylether beta-cyclodextrin.
|
|
JP5072162B2 |
The ionic liquids according to the invention result from the reaction of a halogenated or oxyhalogenated Lewis acid based on titanium, niobium, tantalum, tin or antimony with an organic salt of formula X+A- in which A- is a halide anion ...
|
|
JP2012193194A |
To provide therapeutic compounds.The compounds having formula (I), pharmaceutically acceptable salts, prodrugs, or solvates thereof are provided. The compounds of the formula (I) are used for the treatment of neuronal damage following gl...
|
|
JP2012193183A |
To develop novel analogues of F152.The present invention relates to: compounds having the following formula (I); methods for synthesizing them; and methods for the use thereof in the treatment of various disorders including inflammatory ...
|
|
JP5039268B2 |
The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prod...
|
|
JP5030982B2 |
There is provided a series of novel alpha-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R, R1, R2 and R3 are defined herein, which are inhibitors of beta-amyloid peptide (beta-AP) production and are useful in the treatmen...
|
|
JP5025980B2 |
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds...
|
|
JP5021141B2 |
The instant invention provides processes and intermediates employed in the synthesis of ((2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)-amino-3-hydroxy-5-
(2S-(1-tetrahydropyrimid-2-onyl)-3-methyl-butanoyl)amino-1,6
-diphenylhexane and analogs...
|
|
JP5005852B2 |
Benzoylcyclohexanediones of the formula (I), process for their preparation and their use as herbicides and plant growth regulators are described.In this formula (I), R11, R2, R3, R4, R5, R6 and R7 are various radicals, L is an alkylene c...
|
|
JP4996801B2 |
Rate-controlled particles, comprising compounds of the formula as a solid dispersion.
|
|
JP4991080B2 |
The present invention relates to a method of protecting plants against attack or infestation by phytopathogenic organisms, such as nematodes or especially microorganisms, preferably fungi, bacteria and viruses, or combinations of two or ...
|
|
JP4980726B2 |
In the process for preparing ionic liquids, an ionic liquid is firstly reacted with an alkoxide or with barium hydroxide and is subsequently neutralized with an acid. The ionic liquid contains a phosphonium and/or ammonium cation and an ...
|
|
JP4974438B2 |
This invention comprises the novel compounds of formula (I)
|
|
JP4974439B2 |
This invention comprises the novel compounds of formula (I) wherein r, t, Y1-Y2, R1, R2, R3, R4, R5, R6 and R7 have defined meanings, having farnesyl transferase inhibiting activity; their preparation, compositions containing them and th...
|
|
JP4961095B2 |
The present invention provides analogues of duocarmycins that are potent cytotoxins. Also provided are peptidyl and disulfide linkers that are cleaved in vivo. The linkers are of use in forming prodrugs and conjugates of the cytotoxins o...
|
|
JP4955171B2 |
Disclosed are novel aromatic compounds of the formula (I) wherein G, X, Ar, L and Q are defined herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as...
|
|
JP4936623B2 |
The invention relates to compounds of general formula I, where A<1>, R<1>, R<2 >and Y are as defined in the description; and to their use as phytopathogenic fungicides.
|
|
JP4922539B2 |
This invention describes novel triazole compounds of formula IX: wherein Z1 is nitrogen or CR9 and Z2 is nitrogen or CH, provided that at least one of Z1 and Z2 is nitrogen; G is Ring C or Ring D; Ring C is selected from a phenyl, pyridi...
|
|
JP4911866B2 |
This invention comprises the novel compounds of formula (I) wherein r, s, t, Y1-Y2, R1, R2, R3, R4, R5 and R7 have defined meanings, having farnesyl transferase inhibiting activity; their preparation, compositions containing them and the...
|
|
JP4880849B2 |
Benzoylguanidine derivatives (I) and their salts are new. Benzoylguanidine derivatives of formula (I) and their salts are new. [Image] R 1H, halo, NO 2, CN, (X) o-(CH 2) p-(CF 2) q-CF 3, SO m-R 5, COR 6, CONR 6R 7 or SO 2-NR 6R 7; R 3H, ...
|
|
JP4859264B2 |
The invention relates to ionic compositions having a high ionic conductivity comprising a salt with a delocalized anionic charge.An ionic composition comprises a salt in solution in a solvent and has a conductivity of greater than 10-5 S...
|
|
JP4851085B2 |
The present invention relates to novel pyrrolidine derivative of formula (I), its geometrical isomers, its optically active forms as enantiomers, diastereomers, mixtures of these and its racemate forms, as well as salts thereof, wherein ...
|
|
JP4836396B2 |
The invention relates to novel naphthalene derivatives of formula (I) and their use as cannabinoid receptor agonists wherein X, R 1 , R 2 and R 3 are as defined in the description, processes for their production, their use as pharmaceuti...
|
|
JP4825384B2 |
N-(1,3,5-Triazin-2-yl or pyrimidin-2-yl)-N'-(thien-3-ylsulfonyl or thien-3-ylaminosulfonyl)-ureas (I) are new. Sulfonylureas of formula (I) and their salts are new. [Image] A : N or CH; Q : direct bond or NH; R 1, R 2H, halo or (all opti...
|
|
JP4825664B2 |
The present invention is related to piperazine-2-carboxamide derivatives of formula (I) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery. Wherein A, X,...
|
|
JP4823071B2 |
An organometallic transition metal compound is new. An organometallic transition metal compound of formula (I) is new. Independent claims are also included for: (1) a biscyclopentadienyl ligand system of Formula (II); (2) a catalyst syst...
|
